Treatment of metastatic prostate cancer after STAMPEDE.

about

BH3 Mimetics for the Treatment of Prostate Cancer.

P2860

Q41463153-F160EBDF-DF73-4F6B-A619-CF6D5B40568F

P2860

Treatment of metastatic prostate cancer after STAMPEDE.

Item

http://www.wikidata.org/entity/Q42353513

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Treatment of metastatic prostate cancer after STAMPEDE.

@en

Treatment of metastatic prostate cancer after STAMPEDE.

@nl

type

Item

label

Treatment of metastatic prostate cancer after STAMPEDE.

@en

Treatment of metastatic prostate cancer after STAMPEDE.

@nl

prefLabel

Treatment of metastatic prostate cancer after STAMPEDE.

@en

Treatment of metastatic prostate cancer after STAMPEDE.

@nl

P1476

Treatment of metastatic prostate cancer after STAMPEDE

@en

P2093

Philipp Wolf

http://www.w3.org/2001/XMLSchema#string

P2860

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Androgen deprivation of prostate cancer: Leading to a therapeutic dead end

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Early use of chemotherapy in metastatic prostate cancer.

Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A Review.

P304

315-316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/TAU.2017.02.01

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Philipp Wolf

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28540244

http://www.w3.org/2001/XMLSchema#string

P932

5422685

http://www.w3.org/2001/XMLSchema#string

Treatment of metastatic prostate cancer after STAMPEDE.

about

P2860

P2860

Treatment of metastatic prostate cancer after STAMPEDE.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932